Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Sera Prognostics closes $36mm Series D round

Executive Summary

Sera Prognostics Inc. (proteomics tests for the early prediction of preterm birth defects and other pregnancy-related complications) closed a $36mm Series D round co-led by new investor Blue Ox Healthcare and two undisclosed healthcare companies. Returning backers Domain Associates, InterWest Partners, Laboratory Corp. of America Holdings, Catalyst Health Ventures, and Chione Ltd. also participated. The company will use the proceeds to expand commercialization of and improve its clinically validated PreTRM, a biomarker blood test that assesses individualized risk of premature delivery. Since its 2008 inception, Sera has raised $122mm.
Deal Industry
  • Biotechnology
    • Drug Discovery Tools
      • Genomics-Proteomics
  • In Vitro Diagnostics
    • Chemistry, Immunoassay
    • Molecular Diagnostics & Genetic Testing
Deal Status
  • Final
Deal Type
  • Financing
    • Private Placement

Related Companies